OBJECTIVE: Current suicide risk screening and measurement are inefficient, have limited measurement precision, and focus entirely on suicide-related items. For this study, a psychometric harmonization between related suicide, depression, and anxiety symptom domains that provides a more balanced and complete spectrum of suicidal symptomatology was developed. The objective of this article is to describe the results of the early stages of computerized adaptive testing development for a suicide scale and pave the way for the final stage of validation. METHODS: Data from psychiatric outpatients at the University of Pittsburgh and a community health clinic were collected from January 2010 through June 2012. 789 participants were enrolled in the calibration phase; 70% were female, and 30% were male. The rate of major depressive disorder as diagnosed by DSM-5 was 47%. The item bank contained 1,008 items related to depression, anxiety, and mania, including 11 suicide items. Data were analyzed using a bifactor model to identify a core dimension between suicidal ideation, depression, anxiety, and mania items. A computerized adaptive test was developed via simulation from the actual complete item responses in 308 subjects. RESULTS: 111 items were identified that provided an extension of suicidality assessment to include statistically related responses from depression and anxiety domains that are syndromally associated with suicidality. All items had high loadings on the primary suicide dimension (average = 0.67; range, 0.49-0.88). Analyses revealed that a mean of 10 items (5-20) had a correlation of 0.96 with the 111-item scale, with a precision of 5 points on a 100-point scale metric. Preliminary validation data based on 290 clinician interviews revealed a 52-fold increase in the likelihood of current suicidal ideation across the range of the Computerized Adaptive Test Suicide Scale (CAT-SS). CONCLUSIONS: The CAT-SS is able to accurately measure the latent suicide dimension with a mean of 10 items in approximately 2 minutes. Further validation against an independent clinician-administered assessment of suicide risk (ideation and attempts) and prediction of suicidal behavior is underway.

OBJECTIVE: The capacities of depressed patients to consent to research have been questioned by commentators who fear that the cognitive effects of a disorder may impair subjects' abilities to protect their interests. This study used a new instrument for assessing depressed patients' capacities to consent to research and examined their performance, including the relation between severity of depression and extent of impairment. METHOD: Twenty-six female outpatients with major depression (assessed with the Schedule of Affective Disorders and Schizophrenia-Lifetime Version) enrolled in a study of maintenance psychotherapy were recruited for this project. Consent-related abilities were measured with the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) 1 week after intake and again 8-10 weeks later. Depressive symptoms were measured by the Hamilton Depression Rating Scale. RESULTS: Almost all subjects performed quite well on the capacity measures and maintained that level of performance over time. There was no correlation between performance and degree of depressive symptoms and little relation to prior research experience. Some subjects appeared confused about the extent to which decisions about assignment to treatment groups would be made on the basis of their clinical condition rather than randomly. CONCLUSIONS: This outpatient group with major depression showed few impairments in their decision-making capacities related to research. As in other studies, some concerns were raised about subjects' appreciation that treatment assignments would not be individualized for their needs. Examination of hospitalized patients and those with psychotic depression would help to determine whether they show greater degrees of impairment. The MacCAT-CR was easily adapted for use with this depressed group.